A stable Deep Molecular Response (DMR), defined as BCR::ABL1 transcript levels ≤0.01% determined via RT-qPCR, is the prerequisite for a successful interruption of treatment among patients with CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.